Brief: Selexis And Neximmune Sign Service Agreement To Advance Multiple Immunotherapies Targeting Rare Cancers And Autoimmune Disorders
08/09/2022 13:46
Sept 8 (Reuters) - Neximmune Inc NEXI.O :
* SELEXIS AND NEXIMMUNE SIGN SERVICE AGREEMENT TO ADVANCE
MULTIPLE
IMMUNOTHERAPIES TARGETING RARE CANCERS AND AUTOIMMUNE DISORDERS
Source text for Eikon: ID:nBw4r1glTa
Further company coverage: NEXI.O
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Neximmune
See all newsBrief: Neximmune Appointed Albert Marchio As Interim CFO
Brief: NexImmune and Agents Agreed To Terminate Sales Agreement & ATM Program dated June 2022
Brief: NexImmune Says Co Expects Existing Cash And Cash Equivalents Will Be Sufficient To Meet Its Anticipated Cash Requirements Through Mid-February 2024
Brief: Neximmune Gets Notice From Listing Qualifications Department Of Nasdaq
Brief: NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting